University of Lille

Emmanuel Butstraen appointed as President of Perfumery & Beauty at dsm-firmenich

Retrieved on: 
Monday, May 22, 2023
Integrated Management Concept, University, Integration, MBA, University of Lille, Agricultural engineering, Agricultural productivity, BASF, Firmenich, Perfume, Taste, Management

KAISERAUGST, Switzerland and HEERLEN, Netherlands, May 22, 2023 /PRNewswire/ -- dsm-firmenich is pleased to announce the appointment of Emmanuel Butstraen as the new President of its Perfumery & Beauty business.

Key Points: 
  • KAISERAUGST, Switzerland and HEERLEN, Netherlands, May 22, 2023 /PRNewswire/ -- dsm-firmenich is pleased to announce the appointment of Emmanuel Butstraen as the new President of its Perfumery & Beauty business.
  • Supported by a senior team in the company's Integration Management Office, Emmanuel will continue overseeing the integration while taking on the global leadership role of Perfumery & Beauty.
  • Geraldine Matchett and Dimitri de Vreeze, Co-CEOs of dsm-firmenich, commented: "We are thrilled to announce the appointment of Emmanuel Butstraen as the President of our Perfumery & Beauty business.
  • In his new role as President of Perfumery & Beauty, Emmanuel will report to Co-CEO Dimitri de Vreeze.

AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis

Retrieved on: 
Thursday, December 29, 2022
Multiple, Multiple sclerosis, BTK, MD, Clinical trial, MS, Neurology, ANSM, Disease, Patient, NSPM, Microglia, B cell, Veni, vidi, vici, FOOD, Safety, Pathology, University, FDA, EDSS, PPMS, University of Lille, DRUG, Cell, Neurodegeneration, Randomness, Pharmaceutical industry, Masitinib

AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE SCLEROSIS

Key Points: 
  • AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE SCLEROSIS
    This decision follows authorizations received from several European countries, including the French Agency (ANSM).
  • This is a randomized, double-blind, Phase 3 study to evaluate the safety and efficacy of masitinib 4.5 mg/kg/day in patients with primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (nSPMS).
  • The primary endpoint of the study is the effect of masitinib on time to confirmed disability progression.
  • Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.

OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support

Retrieved on: 
Tuesday, October 25, 2022
GSK, Nadine Opgen-Rhein, Infection, European Investment Bank, Mortality, Securities Act of 1933, University, Acinetobacter baumannii, Tuberculosis, University of Lille, Solution, Adoption, Pneumonia, Bloodstream infections, AMR, Precision medicine, Private Securities Litigation Reform Act, GLOBE, Clinical trial, Phase, FDA, CRO, Rifabutin, Research, Security (finance), Technology, Goal, BSI, Securities Exchange Act of 1934, U.S. Securities and Exchange Commission, TRIC, Drug Quality and Security Act, Patient, Hospital, Subclinical infection, VABP, Nasdaq, Doctor of Philosophy, NGS, GlaxoSmithKline, COVID-19, Pharmaceutical industry, Vaccine, Curetis, MD

To ensure smooth and seamless operations, the Curetis team will train a team of trainers at BioVersys and their clinical research organization (CRO) for the Phase II trial.

Key Points: 
  • To ensure smooth and seamless operations, the Curetis team will train a team of trainers at BioVersys and their clinical research organization (CRO) for the Phase II trial.
  • All data pertaining to the clinical trial will be owned by BioVersys and can be used in their future clinical development and regulatory submissions as needed.
  • Oliver Schacht, PhD, Chief Executive Officer of OpGen Inc. added: The entire OpGen and Curetis team is excited to begin our collaboration with BioVersys and support their Phase II clinical trial of BV100 with our Unyvero platform.
  • This press release includes statements regarding the collaboration agreement entered into by OpGens subsidiary Curetis GmbH and BioVersys AG for their BV100 phase II clinical trial.

EMD Serono Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Retrieved on: 
Wednesday, October 26, 2022
Health, Managed Care, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Immunology, Congress, Merck, RNA transfection, Multiple sclerosis, Science, OLE, MRI, University, Treatment, Hypoesthesia, Infertility, Antigen, Biomarker, SEL, MS, Gene editing, HIV disease progression rates, DBP, Inflammation, Learning, Senior, Cancer, Company, AFL, EMD, Phase, Central nervous system, Merck Millipore, BTK, Health care, Electronics, Lists of diseases, Intelligence, Research, Nerve, Microglia, CNS, ARR, European Committee of the Regions, Merck Serono, Disease, Life, Patient, EDSS, MD, Doctor of Philosophy, Â, RMS, University of Lille, Merck Group, COVID-19, Entrepreneurship, Neurodegeneration, Magnetic resonance imaging, Pharmaceutical industry, Vaccine, Medical imaging, Phosphorus, Biology, Health

In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.

Key Points: 
  • In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.
  • It also has the potential to directly address smoldering inflammation in RMS which contributes to the silent causes of disease progression.
  • It has previously shown promising results in targeting central inflammation, including through its modulatory effects on microglia.
  • Patients experienced sustained and ongoing reductions in blood NfL levels compared to the double-blind period (DBP) and OLE baseline values.

Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Retrieved on: 
Wednesday, October 26, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunology, Congress, RNA transfection, Science, Multiple sclerosis, OLE, MRI, University, Treatment, GMG, Hypoesthesia, Antigen, Biomarker, SEL, Neuromyelitis optica spectrum disorder, MS, Gene editing, HIV disease progression rates, DBP, NMOSD, Inflammation, Interferon beta-1a, Learning, Senior, Company, Neurology, AFL, Phase, Central nervous system, Merck Millipore, BTK, Electronics, Lists of diseases, Intelligence, Nerve, Microglia, CNS, ARR, European Committee of the Regions, SLE, Merck Serono, Disease, Lupus, Patient, EDSS, MD, Doctor of Philosophy, Â, Research, RMS, University of Lille, COVID-19, Entrepreneurship, Neurodegeneration, Magnetic resonance imaging, Pharmaceutical industry, Vaccine, Medical imaging, Phosphorus, Merck, Biology, Health

In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.

Key Points: 
  • In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.
  • It also has the potential to directly address smoldering inflammation in RMS which contributes to the silent causes of disease progression.
  • It has previously shown promising results in targeting central inflammation, including through its modulatory effects on microglia.
  • Patients experienced sustained and ongoing reductions in blood NfL levels compared to the double-blind period (DBP) and OLE baseline values.

Bruker Introduces Enabling New Scientific Capabilities for Cell Biology and Pathobiology Research with High-Field NMR Innovations

Retrieved on: 
Monday, August 22, 2022
Software, Research, General Health, Pharmaceutical, Hardware, Medical Devices, Technology, Health Technology, Science, Biotechnology, Neurology, Health, EPR, Technology, 3D, Biotop, Research, CIC, University of Barcelona, University of Lille Nord de France, Organic acid, MAS, Neurodegeneration, Cell biology, HTS, Hertz, HCN, University, Helium, Cancer, Biochemistry, IDP, Department, Intrinsically disordered proteins, Microscopy, CNRS, University of Lille, NMR, Carbohydrate, Harvard Medical School, Solution, Arthanari, Precision medicine, Metalloprotein, Prion, Multimedia, Membrane protein, Crystallography, Proteomics, 14N, Magic angle spinning, Kelvin, Associate, Dana–Farber Cancer Institute, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, Pharmacology, Internally displaced person, Lyon, Conference, Phosphorylation, Ascend, Life, Medical imaging, Bruker

The new technology also facilitates cell biology research into highly dynamic intrinsically disordered proteins (IDPs) or protein regions that often play key roles in signaling pathways via phosphorylation, e.g.

Key Points: 
  • The new technology also facilitates cell biology research into highly dynamic intrinsically disordered proteins (IDPs) or protein regions that often play key roles in signaling pathways via phosphorylation, e.g.
  • It allows researchers to obtain essential information in crowded IDP spectral regions for the unambiguous assignment of IDP backbone resonances.
  • I am very excited to see which previously inaccessible but important scientific and pathobiology questions this innovative NMR technology can address.
  • Dr. Guido Pintacuda, CNRS Research Director and Director of the Lyon High-field NMR Center explained: The new Bruker 160 kHz MAS HCN probe will push structural, cellular and disease biology research into the next phase of the solid-state NMR scientific evolution.

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Retrieved on: 
Wednesday, May 4, 2022
University of Lille, Paris Descartes University, Euronext, Brain, Hypertension, Drug discovery, University, Union, Twitter, Blood pressure, GLOBE, Development, European Medicines Agency, NDA, Heart failure, Regulatory affairs, Patient, FDA, New Drug Application, Genomics, Research, Head, LinkedIn, Euronext Growth, Pharmaceutical industry, Pharmacy, Sanofi

"I am delighted to join Quantum Genomics and bring my experience in Regulatory Affairs to support the final steps of the clinical development of firibastat in difficult-to-treat/resistant hypertension and heart failure and prepare its first registration by starting with a NDA filing to the FDA," said Sarah Merlen-Boulenger, Head of Regulatory Affairs at Quantum Genomics.

Key Points: 
  • "I am delighted to join Quantum Genomics and bring my experience in Regulatory Affairs to support the final steps of the clinical development of firibastat in difficult-to-treat/resistant hypertension and heart failure and prepare its first registration by starting with a NDA filing to the FDA," said Sarah Merlen-Boulenger, Head of Regulatory Affairs at Quantum Genomics.
  • "The Quantum Genomics team and I are very pleased to welcome Sarah.
  • In addition to accumulating a background of academic excellence, Dr. Boulenger has held various positions in the Regulatory Affairs departments of Sanofi and Ethypharm in France and in the United States.
  • Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the Brain Aminopeptidase A Inhibition (BAPAI) mechanism.

William McBride, Ph.D. is recognized by Continental Who's Who

Retrieved on: 
Monday, April 18, 2022
Society, FISP, List of international sports federations, North American Society for Social Philosophy, Sofia University, International Council, Northwestern University, International Federation of Philosophical Societies, AB, Reciprocity (social and political philosophy), Yale University, University of Lille, Continental, Georgetown University, Organization, Human, Education, Social theory, Employment, BPS Barbara Wilson Lifetime Achievement Award, American, Master of Arts, The Institute for Citizens & Scholars, Multimedia, Industry, Purdue University, University, Philosophy, Political philosophy, Human science, Management, Public relations, Social

Garnering over fifty years of experience in education, Dr. William McBride has led an impressive career.

Key Points: 
  • Garnering over fifty years of experience in education, Dr. William McBride has led an impressive career.
  • Throughout his acclaimed career, Dr. McBride has gained extensive expertise in Social and Political Philosophy, Legal Philosophy, and Continental European Philosophy.
  • Thereafter, Dr. McBride attended the University of Lille from 1959 to 1960, where he was a Fulbright Fellow.
  • Later, Dr. McBride attended Yale University, where he obtained his Master of Arts degree as a Woodrow Wilson Fellow in 1962.

DGAP-News: Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis

Retrieved on: 
Wednesday, April 13, 2022
Protein, RRMS, Clinical trial, Paralysis, Catholic higher education, Wallonia, Multiple sclerosis, Woman, Population, Adult, Peptide, Research, MOG, Muscle weakness, University of Lille, Central nervous system, Patient, Tremor, Spasm, Autoimmune disease, Heredity, Technology, Split of the Catholic University of Leuven, Man, Degenerative disease, Safety, Biology, Disease, University, MS, Health, Attack, CD4, Pharmaceutical industry, Vaccine

"The dosing of the first patient in this study is an important milestone for Imcyse, as we advance our second ImotopeTM into the clinic.

Key Points: 
  • "The dosing of the first patient in this study is an important milestone for Imcyse, as we advance our second ImotopeTM into the clinic.
  • The IMCY-MS-001 Phase 1/2 trial will evaluate IMCY-0141 in adult patients with RRMS.
  • The Phase 2 expansion arm of the trial will be double-blind, randomized, and placebo controlled with an adaptive design.
  • Beyond type 1 diabetes and MS, Imcyse is developing a pipeline of ImotopesTM for the treatment of several autoimmune diseases.

Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope™ IMCY-0141 for Multiple Sclerosis

Retrieved on: 
Wednesday, April 13, 2022
Protein, RRMS, Clinical trial, Paralysis, Catholic higher education, Wallonia, Multiple sclerosis, Woman, Population, Adult, Peptide, Research, MOG, Muscle weakness, University of Lille, Central nervous system, GLOBE, Patient, Tremor, Spasm, Autoimmune disease, Heredity, Technology, Split of the Catholic University of Leuven, Man, Degenerative disease, Safety, Biology, Disease, University, MS, Health, Attack, CD4, Pharmaceutical industry, Vaccine

The dosing of the first patient in this study is an important milestone for Imcyse, as we advance our second Imotope into the clinic.

Key Points: 
  • The dosing of the first patient in this study is an important milestone for Imcyse, as we advance our second Imotope into the clinic.
  • The IMCY-MS-001 Phase 1/2 trial will evaluate IMCY-0141 in adult patients with RRMS.
  • The Phase 2 expansion arm of the trial will be double-blind, randomized, and placebo controlled with an adaptive design.
  • Beyond type 1 diabetes and MS, Imcyse is developing a pipeline of Imotopes for the treatment of several autoimmune diseases.